Comparative Pharmacology
Head-to-head clinical analysis: YONDELIS versus ZANOSAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: YONDELIS versus ZANOSAR.
YONDELIS vs ZANOSAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trabectedin (Yondelis) is a marine-derived alkylating agent that binds to the minor groove of DNA, forming adducts that inhibit transcription and DNA repair. It also modulates the tumor microenvironment by reducing cytokine production and angiogenesis.
Streptozocin, a nitrosourea compound, is a DNA alkylating agent that inhibits DNA synthesis and is selectively toxic to pancreatic beta cells due to preferential uptake via the GLUT2 transporter.
1.5 mg/m2 intravenously over 24 hours every 21 days.
500 mg/m² IV on days 1-5 and 8-12 of a 28-day cycle; or 2-4 mg/kg IV on days 1-5 and 8-12 of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours (range 27-60 hours), supporting a weekly dosing schedule.
Terminal elimination half-life is approximately 5-7 hours; prolonged in renal impairment.
Primarily fecal (approximately 60%) and renal (approximately 22%) as unchanged drug and metabolites. Biliary excretion is a minor route.
Primarily renal (70-80% as unchanged drug). Minor biliary/fecal excretion (<10%).
Category C
Category C
Alkylating Antineoplastic Agent
Alkylating Antineoplastic Agent